Final overall survival analysis of the phase 3 CheckMate 067 trial of nivolumab plus ipilimumab for advanced melanoma

The multinational phase 3 CheckMate 067 trial randomized patients with advanced melanoma 1:1:1 to nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, Final overall survival analysis of the trial, with a minimum follow-up of 10 years, found a median overall survival of 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab monotherapy, and 19.9 months with ipilimumab monotherapy. The hazard ratio for death was 0.53 (95% CI 0.44-0.65) for nivolumab plus ipilimumab as compared with ipilimumab and was 0.63 (0.52-0.76) for nivolumab as compared with ipilimumab. Median melanoma-specific survival was more than 120 months with nivolumab plus ipilimumab (not reached), 49.9 months with nivolumab, and 21.9 months with ipilimumab. Among patients who were alive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus ipilimumab, 97% with nivolumab, and 88% with ipilimumab. The authors conclude that these results showed a continued survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma.